Arkadios Wealth Advisors Grows Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Arkadios Wealth Advisors grew its holdings in Zoetis Inc. (NYSE:ZTS) by 2.5% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 4,924 shares of the company’s stock after acquiring an additional 118 shares during the period. Arkadios Wealth Advisors’ holdings in Zoetis were worth $854,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in ZTS. Norges Bank bought a new stake in Zoetis during the fourth quarter worth approximately $980,646,000. Price T Rowe Associates Inc. MD raised its holdings in Zoetis by 31.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after buying an additional 3,244,074 shares during the period. Sarasin & Partners LLP lifted its position in Zoetis by 546.3% in the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after buying an additional 1,904,899 shares during the last quarter. Swedbank AB purchased a new position in Zoetis during the first quarter worth $210,815,000. Finally, Public Employees Retirement Association of Colorado bought a new position in Zoetis during the fourth quarter valued at $242,757,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Up 0.4 %

NYSE ZTS traded up $0.74 on Friday, reaching $183.63. 93,878 shares of the stock traded hands, compared to its average volume of 2,665,686. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a market cap of $83.19 billion, a price-to-earnings ratio of 35.23, a PEG ratio of 2.78 and a beta of 0.86. The company has a fifty day moving average price of $179.29 and a 200-day moving average price of $174.63. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. Zoetis’s revenue was up 8.3% compared to the same quarter last year. During the same period last year, the company posted $1.41 earnings per share. As a group, research analysts forecast that Zoetis Inc. will post 5.83 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ZTS shares. Piper Sandler raised their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Stifel Nicolaus reaffirmed a “buy” rating and set a $200.00 target price on shares of Zoetis in a research note on Tuesday. The Goldman Sachs Group decreased their price target on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research note on Monday, May 6th. Finally, BTIG Research upped their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $217.11.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.